Comparison

Anti-Human TIGIT (Clone 4E1.2) - Purified in vivo GOLD™ Functional Grade

Item no. LEIN-T810-100mg
Manufacturer Leinco Technologies
Amount 100 mg
Quantity options 1 mg 100 mg 25 mg 5 mg 50 mg
Category
Type Antibody Monoclonal
Applications FC, other, IV
Clone 4E1.2
Specific against Human (Homo sapiens)
Host Mouse
Isotype IgG3 kappa
Purity ≥95% monomer by analytical SEC, >95% by SDS Page
NCBI 201633
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping Condition Cool pack
Available
Manufacturer - Category
Purified in vivo Functional Grade>Gold Purified Bulk Antibodies|Primary Monoclonal Antibodies>Immune Checkpoints
Manufacturer - Targets
TIGIT
Shipping Temperature
Next Day 2-8°C
Storage Conditions
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles. Note: This antibody is prone to precipitation at 2-8°C resulting in a slight opaque white liquid. At room temperature liquid is clear and colorless.
Product Description
TIGIT (WUCAM) is an immunoreceptor that inhibits multiple immune cell responses, including T cell priming by dendritic cells, tumor cell killing by NK cells and cytotoxic T cells, and also enhances the immune suppressive activity of regulatory T cells1. TIGIT is a novel member of the Ig-superfamily distantly related to Nectins and Necls that aligns with the distal Ig-V-type domains of Nectin(1-4), poliovirus receptor (PVR; CD155), DNAM-1 (CD226), and TACTILE (CD96)2. TIGIT is preferentially expressed on human B helper follicular T cells and binds with high affinity to PVR under both static and flow conditions. Additionally, TIGIT, DNAM-1, and TACTILE are expressed together on T cells and NK cells and share PVR as a ligand1. TIGIT is not detectable on the surface of resting peripheral blood mononuclear cells from healthy donors unless activated2.
4E1.2 was generated by immunizing BALB/c mice with TIGITFLAG-Baf3 cells2. Baf3 cells transfected with TIGIT cDNA are specifically stained by 4E1.2. Blocking with 4E1.2 significantly reduces PVR-hFc binding to TIGIT/Baf3 and to ICOShigh CD4+ T cells. TIGIT-PVR interactions are important for regulating T cell function and contribute to T cell-dependent B cell responses.
TIGIT is an attractive target for cancer therapy due to its role as an immune checkpoint1. Immunotherapy targeting TIGIT and the PD-1/PD-L1 pathway is capable of tumor suppression. Other combinations, such as TIGIT with TIM-3, CD112R, or TACTILE, have also shown promise in blocking studies.
Concentration
≥ 5.0 mg/ml
Formulation
This monoclonal antibody is aseptically packaged and formulated in 200 mM arginine, 50 mM histidine, and 100 mM NaCl at a pH of 6.4 – 6.6, with no carrier protein, potassium or preservatives added Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Antigen Distribution
TIGIT is expressed on activated CXCR5+CD4+ T cells in peripheral blood, variably on CD8+ T cells and CD56+CD3- NK cells, and constitutively in tonsils on some CD3+CD8int T cells as well as the CXCR5high/ICOShigh subset of CD4+ T cells that contains fully differentiated TFH cells.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close